Loading…
Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.
Italian maker of glass vials, syringes and drug-containment/delivery systems for the pharmaceutical and biotech industry.
Sells containers by the unit to drugmakers, and orders recur as customers fill batches of their drugs, so demand follows their injectable volumes. A founding family controls it through a holding company. Engineering sales of machines used on packaging lines are lumpier, project-style business.
Moat: narrow (customer qualification, IP / patents, switching costs). Packaging components are qualified in customers' regulatory drug filings, making switching costly and slow.
Headquarters: Piombino Dese, Italy · Founded: 1949
Size Stevanato (STVN) is a United States Health Care company (Medical Specialties) with a market value of $3.70B, the 1393rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.57 on 6 Nov 2026.
Performance Over six months the shares fell 25.6%, against +6.2% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 12.0% over the last twelve months (peer median +3.4%); the operating margin is 17.6% (peer median 11.0%).
Valuation It trades at 19.3× forward earnings against a peer median of 20.6× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.7 points above its cost of capital (8.4% WACC).
Short interest Short interest is 1.9% of the free float (15 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.45B | $1.34B | $1.19B | $1.17B | $1.03B |
| Revenue growth | — | +12% | +2% | +14% | — |
| Gross profit | $418M | $375M | $316M | $353M | $324M |
| EBITDA | $369M | $315M | $252M | $291M | $251M |
| Net income | $163M | $158M | $127M | $157M | $150M |
| Free cash flow | $14.4M | $25.2M | -$159M | -$355M | -$138M |
| Capital expenditure | $308M | $310M | $339M | $478M | $256M |
| Total debt | $533M | $551M | $444M | $440M | $233M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Stevanato STVN | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% |
| West Pharmaceutical Services WST | $27.9B | +23% | +13% | 23% | 39.8× | 25.2% |
| Gerresheimer GXI.DE | $1.21B | +24% | +9% | -4% | 18.0× | 55.8% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.4% | +9.0% | 2nd lowest of 21 |
| 6-month return | -25.6% | +6.2% | 3rd lowest of 21 |
| Distance from 52-week high | -49.7% | -22.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +12.0% | +3.4% | 4th highest of 19 |
| Operating margin | 17.6% | 11.0% | 3rd highest of 19 |
| Forward P/E | 19.3× | 20.6× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 10.6% | 8.2% | 8th most demanding of 17 |
| Growth delivered (Del g) | +12.1% | +7.6% | highest of 17 |
| Hurdle (Req g minus delivered) | -1.6 pp | +1.1 pp | 6th least demanding of 17 |
| ROIC minus cost of capital | +0.7 pp | -1.2 pp | 8th highest of 18 |
| EV / EBITDA | 11.1× | 11.5× | 5th cheapest of 10 |
| Net debt / EBITDA | 1.1× | 0.5× | 5th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |